Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference

Rhea-AI Summary

Oragenics (NYSE American: OGEN) announced its participation in the 15th Annual Traumatic Brain Injury Conference in Boston, MA on May 5-6, 2025. The company's Chief Clinical Officer, Dr. W. Frank Peacock, will present updates on the HeadSMART II trial, one of the largest U.S. emergency department biomarker discovery studies for mild traumatic brain injury (mTBI).

The study, expected to enroll over 2,000 patients within the next year, is conducted in collaboration with BrainBox Solutions. This partnership aims to develop a comprehensive test-to-treat platform combining BrainBox's diagnostics with Oragenics' intranasal therapeutic candidate, ONP-002.

The conference brings together leaders from academia, industry, government, and military to discuss advances in TBI research and clinical care, focusing on diagnosis, treatment, and long-term outcomes for TBI survivors.

News Market Reaction

+3.74%

1 alert

+3.74% News Effect

On the day this news was published, OGEN gained 3.74%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing novel intranasal therapies for concussion and brain-related conditions, today announced its participation in the 15th Annual Traumatic Brain Injury Conference, taking place May 5-6, 2025 in Boston, MA.

Hosted by Arrowhead Sci-Tech Conferences & Events, the Annual Traumatic Brain Injury Conference brings together global leaders from academia, industry, government, and the military to share the latest advancements in TBI research and clinical care. The event provides a platform for cross-sector collaboration on diagnosis, treatment, and long-term outcomes for TBI survivors.

Oragenics will be represented by Dr. W. Frank Peacock, MD, FACEP, FACC, FESC, Chief Clinical Officer of Oragenics and Professor, Vice Chair for Research at Baylor College of Medicine, presenting, “An Update on HeadSMART II: Advancing Precision Strategies for Traumatic Brain Injury Detection and Management”.

The presentation will highlight data from HeadSMART II, one of the largest ongoing U.S. emergency department prospective biomarker discovery trials for mild traumatic brain injury (mTBI). The study is expected to surpass 2,000 enrolled patients within the next year. Findings from HeadSMART II may significantly reshape the understanding of the mTBI population and influence future clinical trial enrollment strategies in the field.

Oragenics is participating in the HeadSMART II trial in collaboration with BrainBox Solutions, a leader in precision diagnostics for brain injury, as part of its broader commitment to advancing the early detection, treatment, and clinical management of concussions and other brain injuries. This collaboration builds on the strategic partnership announced earlier this year, aimed at creating a comprehensive test-to-treat platform for mild traumatic brain injury by combining BrainBox’s diagnostic technologies with Oragenics’ intranasal therapeutic candidate, ONP-002. Read the full announcement here.

For more information on the conference, visit https://tbiconference.com/

Investor Contact

Rich Cockrell
866.889.1972
ogen@cg.capital

About Oragenics, Inc.

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration. For more information, visit www.oragenics.com.

FAQ

What is the HeadSMART II trial that Oragenics (OGEN) is presenting at the TBI Conference 2025?

HeadSMART II is one of the largest ongoing U.S. emergency department biomarker discovery trials for mild traumatic brain injury (mTBI), expected to enroll over 2,000 patients within the next year.

How is Oragenics (OGEN) collaborating with BrainBox Solutions for TBI treatment?

Oragenics is partnering with BrainBox Solutions to create a comprehensive test-to-treat platform that combines BrainBox's diagnostic technologies with Oragenics' intranasal therapeutic candidate ONP-002.

When and where is Oragenics (OGEN) presenting at the Traumatic Brain Injury Conference?

Oragenics is presenting at the 15th Annual Traumatic Brain Injury Conference in Boston, MA, taking place May 5-6, 2025.

What therapeutic candidate is Oragenics (OGEN) developing for brain injury treatment?

Oragenics is developing ONP-002, an intranasal therapeutic candidate for concussion and brain-related conditions.

Who will represent Oragenics (OGEN) at the 2025 TBI Conference?

Dr. W. Frank Peacock, Chief Clinical Officer of Oragenics and Professor at Baylor College of Medicine, will represent the company at the conference.